{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:21:23Z","timestamp":1707524483712},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,9]]},"DOI":"10.7759\/cureus.22061","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T18:59:02Z","timestamp":1644433142000},"source":"Crossref","is-referenced-by-count":0,"title":["Use of Systemic Anticoagulation in COVID-19: Delving Beyond Theoretical Hypothesis"],"prefix":"10.7759","author":[{"given":"Christopher","family":"Millet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spandana","family":"Narvaneni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fady","family":"Shafeek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherif","family":"Roman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashesha","family":"Mechineni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajapriya","family":"Manickam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1936","article-title":"Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review","volume":"369","author":"Dagens A","year":"2020","unstructured":"Dagens A, Sigfrid L, Cai E, et al.. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review. BMJ. 2020, 369:m1936. 10.1136\/bmj.m1936","journal-title":"BMJ"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2020.03.006","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","volume":"50","author":"Molina JM","year":"2020","unstructured":"Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, de Castro N. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020, 50:384. 10.1016\/j.medmal.2020.03.006","journal-title":"Med Mal Infect"},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.7196\/SAMJ.2020.v110i12.15328","article-title":"Rapid evolution of our understanding of the pathogenesis of COVID- 19: Implications for therapy","volume":"110","author":"Mustafa F","year":"2020","unstructured":"Mustafa F, Giles R,Pepper M.S.. Rapid evolution of our understanding of the pathogenesis of COVID- 19: Implications for therapy. South African Medical Journal. 2020, 110:1180-1185.","journal-title":"South African Medical Journal"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01660","article-title":"High-dose intravenous immunoglobulins in the treatment of severe acute viral pneumonia: the known mechanisms and clinical effects","volume":"11","author":"Liu X","year":"2020","unstructured":"Liu X, Cao W, Li T. High-dose intravenous immunoglobulins in the treatment of severe acute viral pneumonia: the known mechanisms and clinical effects. Front Immunol. 2020, 11:1660. 10.3389\/fimmu.2020.01660","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"323","author":"Sanders JM","year":"2020","unstructured":"Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020, 323:1824-36. 10.1001\/jama.2020.6019","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby P","year":"2021","unstructured":"Horby P, Lim WS, Emberson JR, et al.. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021, 384:693-704. 10.1056\/NEJMoa2021436","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.30476\/ijms.2020.87233.1730","article-title":"Clinical experience, pathophysiology, and considerations in the prophylaxis and treatment of hypercoagulopathy of COVID-19: a review study","volume":"46","author":"Pourafkari L","year":"2021","unstructured":"Pourafkari L, Mirza-Aghzadeh-Attari M, Zarrintan A, Mousavi-Aghdas SA. Clinical experience, pathophysiology, and considerations in the prophylaxis and treatment of hypercoagulopathy of COVID-19: a review study. Iran J Med Sci. 2021, 46:1-14. 10.30476\/ijms.2020.87233.1730","journal-title":"Iran J Med Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen N","year":"2020","unstructured":"Chen N, Zhou M, Dong X, et al.. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020, 395:507-13. 10.1016\/S0140-6736(20)30211-7","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006520","article-title":"COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection","volume":"136","author":"Al-Samkari H","year":"2020","unstructured":"Al-Samkari H, Karp Leaf RS, Dzik WH, et al.. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020, 136:489-500. 10.1182\/blood.2020006520","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19","volume":"385","author":"Lawler PR","year":"2021","unstructured":"Lawler PR, Goligher EC, Berger JS, et al.. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med. 2021, 385:790-802. 10.1056\/NEJMoa2105911","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.05.001","article-title":"Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19","volume":"76","author":"Paranjpe I","year":"2020","unstructured":"Paranjpe I, Fuster V, Lala A, et al.. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020, 76:122-4. 10.1016\/j.jacc.2020.05.001","journal-title":"J Am Coll Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n311","article-title":"Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study","volume":"372","author":"Rentsch CT","year":"2021","unstructured":"Rentsch CT, Beckman JA, Tomlinson L, et al.. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. BMJ. 2021, 372:n311. 10.1136\/bmj.n311","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.4152","article-title":"Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION Randomized Clinical Trial","volume":"325","author":"Sadeghipour P","year":"2021","unstructured":"Sadeghipour P, Talasaz AH, Rashidi F, et al.. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION Randomized Clinical Trial. JAMA. 2021, 325:1620-30. 10.1001\/jama.2021.4152","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01203-4","article-title":"Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial","volume":"397","author":"Lopes RD","year":"2021","unstructured":"Lopes RD, de Barros E Silva PG, Furtado RH, et al.. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021, 397:2253-63. 10.1016\/S0140-6736(21)01203-4","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26102","article-title":"Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis","volume":"96","author":"Meizlish ML","year":"2021","unstructured":"Meizlish ML, Goshua G, Liu Y, et al.. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis. Am J Hematol. 2021, 96:471-9. 10.1002\/ajh.26102","journal-title":"Am J Hematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005493","article-title":"American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients","volume":"5","author":"Cuker A","year":"2021","unstructured":"Cuker A, Tseng EK, Nieuwlaat R, et al.. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. Blood Adv. 2021, 5:3951-9. 10.1182\/bloodadvances.2021005493","journal-title":"Blood Adv"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.08.041","article-title":"Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19","volume":"76","author":"Nadkarni GN","year":"2020","unstructured":"Nadkarni GN, Lala A, Bagiella E, et al.. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol. 2020, 76:1815-26. 10.1016\/j.jacc.2020.08.041","journal-title":"J Am Coll Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15022","article-title":"The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience","volume":"18","author":"Pesavento R","year":"2020","unstructured":"Pesavento R, Ceccato D, Pasquetto G, et al.. The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience. J Thromb Haemost. 2020, 18:2629-35. 10.1111\/jth.15022","journal-title":"J Thromb Haemost"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000004472","article-title":"Incidence of venous thromboembolism in critically ill coronavirus disease 2019 patients receiving prophylactic anticoagulation","volume":"48","author":"Trigonis RA","year":"2020","unstructured":"Trigonis RA, Holt DB, Yuan R, et al.. Incidence of venous thromboembolism in critically ill coronavirus disease 2019 patients receiving prophylactic anticoagulation. Crit Care Med. 2020, 48:e805-8. 10.1097\/CCM.0000000000004472","journal-title":"Crit Care Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14929","article-title":"Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19","volume":"18","author":"Spyropoulos AC","year":"2020","unstructured":"Spyropoulos AC, Levy JH, Ageno W, et al.. Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020, 18:1859-65. 10.1111\/jth.14929","journal-title":"J Thromb Haemost"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2018.08.010","article-title":"Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients","volume":"7","author":"Obi AT","year":"2019","unstructured":"Obi AT, Tignanelli CJ, Jacobs BN, et al.. Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients. J Vasc Surg Venous Lymphat Disord. 2019, 7:317-24. 10.1016\/j.jvsv.2018.08.010","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007%2Fs11239-020-02138-z","article-title":"Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum","volume":"50","author":"Barnes GD","year":"2020","unstructured":"Barnes GD. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. 2020, 50:72-81. 10.1007%2Fs11239-020-02138-z","journal-title":"J Thromb Thrombolysis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.04.031","article-title":"COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic Therapy, and follow-up: JACC state-of-the-art review","volume":"75","author":"Bikdeli B","year":"2020","unstructured":"Bikdeli B, Madhavan MV, Jimenez D, et al.. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic Therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020, 75:2950-73. 10.1016\/j.jacc.2020.04.031","journal-title":"J Am Coll Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.05.559","article-title":"Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST Guideline and Expert Panel Report","volume":"158","author":"Moores LK","year":"2020","unstructured":"Moores LK, Tritschler T, Brosnahan S, et al.. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST Guideline and Expert Panel Report. Chest. 2020, 158:1143-63. 10.1016\/j.chest.2020.05.559","journal-title":"Chest"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/84473-use-of-systemic-anticoagulation-in-covid-19-delving-beyond-theoretical-hypothesis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:38:16Z","timestamp":1707507496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/84473-use-of-systemic-anticoagulation-in-covid-19-delving-beyond-theoretical-hypothesis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.22061","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,9]]}}}